Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic

PHASE3CompletedINTERVENTIONAL
Enrollment

275

Participants

Timeline

Start Date

April 3, 2020

Primary Completion Date

June 25, 2020

Study Completion Date

December 31, 2020

Conditions
COVID-19
Interventions
DRUG

Hydroxychloroquine

"Hydroxychloroquine with the following dosage:~* day 0: 400 mg (2 tablets)~* day 1: 400 mg (2 tablets)~* day 2: 400 mg (2 tablets)~* day 3: 400 mg (2 tablets)~* weekly: 400 mg (2 tablets) for a period of six months"

DRUG

Placebos

"Placebo with the following dosage:~* day 0: 400 mg (2 tablets)~* day 1: 400 mg (2 tablets)~* day 2: 400 mg (2 tablets)~* day 3: 400 mg (2 tablets)~* weekly: 400 mg (2 tablets) for a period of six months"

Trial Locations (1)

08036

ISGlobal, Barcelona

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Hospital Clinic of Barcelona

OTHER

collaborator

Laboratorios Rubió

UNKNOWN

collaborator

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

OTHER

collaborator

Hospital Plató

OTHER

collaborator

Hospital de Granollers

OTHER

lead

Barcelona Institute for Global Health

OTHER

NCT04331834 - Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic | Biotech Hunter | Biotech Hunter